Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
People newly diagnosed with HIV must be able to access treatment and support, which could be improved if guided by people who have been taken the test themselves, researchers found.
Study results of an intervention that includes a custom smartphone app tailored to the needs and preferences of a rural population of people with HIV living in the southern U.S.
"Since this appears to be a 'best in class' drug, doravirine has enough advantages that it is a useful advance in HIV therapy, if not a transformational one," writes Paul Sax, M.D.
On Aug. 30, 2018, the U.S. FDA approved doravirine as a separate formulation for use with ART and in a fixed-dose combination with generic tenofovir DF and lamivudine (3TC).
After 96 weeks, more people achieved viral suppression on a doravirine-based antiretroviral drug regimen compared with a darunavir (Prezista)-based one, according to data presented at the recent 22nd International AIDS Conference.
The first global comparison of adolescents who acquired HIV as newborns highlights the challenges around treatment for children in developing countries.
On July 17, 2018 the U.S. Food and Drug Administration approved Symtuza, a four-drug combination indicated as a complete regimen for the treatment of HIV-1 infection in adults.
Study Shows Depressive Symptoms Associated With Detectable HIV Viral Load, but Not With Missed Visits
Adherence to HIV care visits was associated more with mental health conditions before starting antiretroviral treatment than with recent depressive symptoms, while a detectable viral load was related to such symptoms.
On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC.